SK Biopharm's CTO On Diversity In Open Innovation

Primarily Looking At Oncology, CNS Collaborations

SK Biopharm’s chief technology officer outlines how the company’s open innovation strategy may vary and what he sees as essential in new drug development.

diversity
Drawing Proper Initial Sketch Is Key To Successful Development • Source: Shutterstock

With Korean pharmas competitively stepping up open innovation activities, CNS-focused SK Biopharmaceuticals Co., Ltd is also pursuing a more open collaboration approach than in the past, seeking diversity in modalities, therapeutic areas and indications to achieve growth and synergies.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By 

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By 

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.

China’s Biotech Stocks Proved More Resilient Than US’s Amid Market Turmoil

 

Start-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.

More from Scrip

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By 

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By 

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

Sanofi Licenses Bispecific Candidates From AI-Driven Earendil

 
• By 

Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.